(COLL) Collegium Pharmaceutical, Inc. Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(COLL) Collegium Pharmaceutical, Inc. Complete Analysis Pack
A Must-Have Tool for Decision-Makers
This Collegium Pharmaceutical, Inc. Porter's Five Forces Analysis helps you assess the competitive forces shaping the company’s market, including rivalry, suppliers, buyers, substitutes, and new entrants. The page already shows a real preview of the report content, so you can review it before buying. Purchase the full version for the complete ready-to-use analysis.
Suppliers Bargaining Power
API and formulation input dependence
Collegium Pharmaceutical, Inc. relies on specialized active pharmaceutical ingredients and formulation inputs for pain therapies, so supplier power is not trivial. Suppliers that meet strict FDA and controlled-substance quality rules can charge more and slow switching. Still, Collegium can qualify alternate sources over time, which helps limit concentration risk and keeps bargaining power from staying high.
Controlled substance manufacturing constraints
Manufacturing Collegium Pharmaceutical, Inc.'s oxycodone and tapentadol products needs DEA Schedule II controls, validated plants, and tight chain-of-custody systems. That lifts switching costs if a contract manufacturer slips on quality or compliance. Still, large pharma service providers compete hard for long-term supply deals, which caps supplier power. The result is a moderate but sticky supplier risk.
Packaging and abuse-deterrent expertise
Xtampza ER’s abuse-deterrent design and tight packaging specs give suppliers more leverage than commodity vendors, because few partners can meet the formulation and serialization needs. Still, Collegium can offset that by splitting work across contract manufacturers and packaging partners with similar capabilities, which keeps switching options open.
Regulatory compliance burden
Collegium Pharmaceutical, Inc.’s suppliers face 3 heavy gates: FDA, DEA, and quality-system rules. That shrinks the qualified vendor pool, so approved suppliers can push harder on price and terms. Because one failure can stop pain-medicine supply, Collegium has to keep backups and audit controls in place.
- Fewer qualified vendors
- Higher supplier leverage
- Backup suppliers reduce risk
- Audits raise compliance discipline
Limited raw-material differentiation
Collegium Pharmaceutical, Inc. faces moderate supplier power because most excipients, packaging, and distribution services are commoditized, so switching costs stay low. The pressure rises only for specialized inputs tied to opioid manufacturing and abuse-deterrent delivery, where qualified sources are narrower and substitution is harder. That keeps input risk real, but not broad-based.
- Basic inputs: low differentiation, moderate power
- Specialized opioid inputs: tighter supply, higher power
- Distribution: usually competitive and replaceable
Collegium’s Supplier Power Is Moderate, But Key Inputs Stay Hard to Replace
Collegium Pharmaceutical, Inc. has moderate supplier power because its 2 core pain brands depend on FDA, DEA, and quality-approved inputs. Basic excipients and logistics are replaceable, but specialized opioid and abuse-deterrent inputs are harder to source. That keeps leverage with suppliers real, but not dominant.
| Input type | Supplier power | Why it matters |
|---|---|---|
| Basic excipients | Low | Many substitutes |
| Controlled-substance inputs | High | Few qualified vendors |
| CMOs and packaging | Moderate | Switching needs validation |
What is included in the product
Detailed Word Document
Assesses Collegium Pharmaceutical, Inc.’s competitive pressures from rivals, buyers, suppliers, new entrants, and substitutes.
Customizable Excel Spreadsheet
A quick, one-page view of Collegium Pharmaceutical’s five forces—making competitive pressure easy to spot and act on.
Reference Sources
Provides a clear source trail for Collegium Pharmaceutical, Inc., helping teams verify claims quickly and make decisions with more confidence.
Customers Bargaining Power
PBM and insurer control
PBM and insurer control is high: the three biggest PBMs manage about 80% of U.S. prescriptions, so they can force rebates, discounts, and formulary deals before giving coverage. That pressure hits Collegium Pharmaceutical, Inc. on price and net revenue, especially for pain drugs that need access on major plans.
Hospital and channel purchasing pressure
Hospitals, health systems, and large pharmacy chains buy in bulk, so they can press hard on price, rebates, and formulary access. That makes switching fast: one coverage change can move share between branded and generic pain therapies almost overnight. For Collegium Pharmaceutical, Inc., the fight is not just clinical value; it is also economics, access, and net cost per patient.
Prescriber influence on demand
Physicians strongly shape demand for Collegium Pharmaceutical, Inc.'s Xtampza ER, Nucynta ER, and Nucynta IR by choosing whether to prescribe them, so clinical preference and safety views matter a lot. But they are not the final buyer, and payer controls like prior authorization and formulary access still decide many fills. That keeps customer power moderate, not high.
Patient affordability sensitivity
Patients are highly price sensitive in Collegium Pharmaceutical, Inc. pain drugs because therapy is recurring and high copays can trigger abandonment or switching. In 2025, Medicare Part D’s out-of-pocket cap fell to $2,000, but many commercially insured patients still face sharp monthly cost swings that can hit refill rates. Collegium has to keep copays low to protect adherence and persistence.
High copays raise abandonment risk.
Recurring pain care amplifies refill sensitivity.
Lower out-of-pocket costs support persistence.
Formulary access dependence
Formulary access is a real pressure point for Collegium Pharmaceutical, Inc.: if a drug drops out of preferred coverage, script volume can fall fast because PBMs and payers steer patients to lower-cost options. In 2024, Collegium Pharmaceutical, Inc. reported net product revenue of about $700 million, so even small access changes can move sales. Coverage talks matter as much as new prescriptions.
- PBMs can shift demand quickly.
- Preferred status supports volume.
- Loss of coverage hurts leverage.
- Collegium Pharmaceutical, Inc. must defend access.
PBMs Hold the Upper Hand Over Collegium’s Access and Pricing
Customer power is high for Collegium Pharmaceutical, Inc. because PBMs, insurers, and large buyers can force rebates, prior auth, and formulary cuts before access. The top 3 PBMs handle about 80% of U.S. prescriptions, so they can shift volume fast. Patients also react to cost: the Medicare Part D out-of-pocket cap is $2,000 in 2025, but commercial copays can still hurt fills.
| Factor | Data |
|---|---|
| Top 3 PBMs | ~80% of U.S. scripts |
| Medicare OOP cap | $2,000 in 2025 |
| Collegium revenue | ~$700M in 2024 |
What You See Is What You Get
Collegium Pharmaceutical, Inc. Porter's Five Forces Analysis
This preview shows the exact Collegium Pharmaceutical, Inc. Porter's Five Forces Analysis you’ll receive after purchase—no placeholders, no sample text. It’s the same professionally written, ready-to-use document displayed here in full. Once you complete your order, you’ll get instant access to this exact file.
Rivalry Among Competitors
Branded opioid competition
Collegium faces meaningful rivalry in branded pain care because rivals sell to the same prescribers and patients, and some have bigger sales forces and deeper portfolios. In the U.S., the branded analgesics market is still crowded, and prescriber loyalty can be hard to win back once it shifts. That keeps pricing and access pressure high even in a niche.
Generic substitution pressure
Generic opioid drugs keep price pressure high, because payers can choose far cheaper options than Xtampza ER. Even with abuse-deterrent design, Collegium Pharmaceutical, Inc. still has to prove the premium is worth it versus low-cost generics in a market where oxycodone products are widely substitutable. That makes competitive rivalry strong, since differentiation must offset payer steering and rebate pressure.
Non-opioid pain treatment alternatives
Non-opioid pain care is crowded, with 3 core rivals often used first: NSAIDs, acetaminophen, and gabapentinoids. As clinicians keep shifting away from opioids, these options can squeeze demand for Collegium Pharmaceutical, Inc. products. To defend share, Collegium needs clear clinical evidence, payer access, and proof of patient-specific benefit.
Lifecycle and patent-based competition
Collegium Pharmaceutical, Inc. faces rivalry that is shaped by patent cliffs and product life cycles: in branded pain drugs, generic entry can wipe out 80%-90% of sales in the first year after loss of exclusivity. That makes timing gaps, label tweaks, and improved release forms key weapons, because a small shift in prescribing can move a lot of revenue.
For Collegium Pharmaceutical, Inc., this means competition is not just about price; it is about defending high-value prescriptions for products like Xtampza ER and Belbuca while rivals look for openings in formulation or access. The result is a tighter fight for a smaller pool of scripts, and that keeps rivalry intense even when the market size looks stable.
- Patent expiry can trigger fast generic erosion.
- Label changes can shift prescribing quickly.
- Improved formulations can win share fast.
- High-value scripts make rivalry more intense.
Promotion and access battles
Promotion and access battles matter as much as product quality because Collegium Pharmaceutical, Inc. must keep payer access, prescriber awareness, and pharmacy reach for brands like Xtampza ER and Belbuca. In pain care, small formulary shifts can swing script flow fast, so sales execution is a repeat test, not a one-time win.
- Win payer contracts first.
- Protect formulary status.
- Drive prescriber awareness.
- Expand distribution reach.
Collegium Pharmaceutical, Inc. needs to win these access fights again and again to keep revenue steady.
Collegium Faces Fierce Rivalry and Heavy Generic Pressure
Competitive rivalry is strong because Collegium Pharmaceutical, Inc. fights for a small pool of pain scripts against branded, generic, and non-opioid options. Generic entry can cut branded sales by 80%-90% in year one, so access, formulary status, and prescriber loyalty matter as much as product quality.
| Force | Key signal |
|---|---|
| Rivalry | Strong; Xtampza ER and Belbuca face payer and generic pressure |
Substitutes Threaten
Non-opioid analgesics
NSAIDs and acetaminophen are widely sold OTC, and many generic 100-count bottles are under $10 at U.S. retailers. That low price and easy access make them strong substitutes for patients whose pain can be handled without opioids, which caps demand for Collegium Pharmaceutical, Inc.'s therapies when a lower-risk option is enough.
Interventional pain procedures
Interventional pain procedures like injections and nerve blocks can lower the need for long-term oral opioids, so they act as a real substitute in specialty pain care. For chronic pain, these options are often preferred when targeted relief is needed, especially in patients who want to avoid daily opioid use. With chronic pain affecting about 20% of U.S. adults, the addressable market for these procedures is large, which keeps substitution pressure meaningful for Collegium Pharmaceutical, Inc.
Physical and behavioral therapies
For Collegium Pharmaceutical, Inc., physical therapy, rehabilitation, and behavioral therapy are real substitutes in chronic pain care, especially as clinicians push non-drug options first. The CDC says 20.9% of U.S. adults had chronic pain and 6.9% had high-impact chronic pain, so the pool for these alternatives is large. As these therapies expand, they can lower long-term demand for branded opioid prescriptions.
Safer prescribing preferences
Clinicians and payers still favor lower-risk options, so opioid scripts can lose share even when they work. In 2024, the U.S. had about 80,000 drug overdose deaths, which keeps misuse risk front and center for prescribing and coverage decisions. Abuse-deterrent designs help Collegium Pharmaceutical, Inc., but they do not remove the substitute threat.
- Safety drives payer choice
- Lower-risk therapies can win share
- Abuse-deterrent is not a full shield
Patient and payer avoidance of opioids
Public health pressure keeps patient and payer avoidance of opioids high, so substitutes like non-opioid pain drugs, injections, and physical therapy can limit demand for Collegium Pharmaceutical, Inc.'s Xtampza ER and Nucynta. This makes volume growth harder and leaves substitute pressure as a core strategic risk.
- Non-opioid options keep share gains away.
- Payers often prefer lower-risk therapies.
- Access barriers can cap script growth.
Cheap pain alternatives keep pressure on Collegium high
Substitute pressure on Collegium Pharmaceutical, Inc. stays high because OTC NSAIDs and acetaminophen are cheap, while injections, nerve blocks, PT, and behavioral care can replace opioids in many pain cases. With 20.9% of U.S. adults reporting chronic pain and 6.9% high-impact pain, payers still have many non-opioid paths to choose from.
| Substitute | Why it matters |
|---|---|
| OTC pain meds | Low cost, easy access |
| Non-drug care | Can reduce opioid use |
Entrants Threaten
Heavy regulatory barriers
Heavy regulatory barriers keep new entrants out of Collegium Pharmaceutical, Inc.'s pain market. Any firm must clear FDA, DEA, and state controlled-substance rules, and those reviews can take months to years while adding high legal, quality, and compliance costs. That makes entry hard for smaller companies without deep regulatory teams and capital.
High clinical and legal risk
Opioid developers face extreme clinical and legal risk, which raises the threat of new entrants for Collegium Pharmaceutical, Inc. U.S. opioid settlements have topped $50 billion, and ongoing DEA, FDA, and state compliance demands make the category costly to enter. New players must spend heavily on legal defense, risk controls, and post-market monitoring, so many stay out.
Manufacturing and security requirements
Controlled-substance manufacturing needs secure sites, validated processes, and diversion controls, with oversight from both the FDA and DEA. That makes entry slow and costly, not a quick copy-and-launch move. For Collegium Pharmaceutical, Inc., those barriers favor scale players that can fund compliance, security, and quality systems before selling a single dose.
Need for payer and prescriber access
Even after FDA approval, a new drug still needs payer coverage and clinician adoption, which is a hard hurdle for Collegium Pharmaceutical, Inc. In pain care, formulary access and prescriber trust often take months and heavy rebate spend, so a new entrant can burn cash before sales scale. Established payer ties and the 1,000-plus prescriber and account touchpoints needed to move volume make entry less attractive.
- Approval is not enough.
- Formulary access drives volume.
- Prescriber trust is slow to build.
- Launch costs hit before revenue.
Brand trust and differentiation hurdle
Collegium Pharmaceutical, Inc. has a strong moat because its brands depend on trust in abuse-deterrent performance and steady supply. New entrants must prove the same safety and value while fighting entrenched brands and low-cost generics, which already fill about 90% of U.S. prescriptions. That makes meaningful entry costly and slow.
- Trust is a key buying filter.
- Abuse-deterrent proof is hard to copy.
- Generics compress price and share.
- Supply reliability also matters.
Strong Barriers Keep New Pain Drug Entrants Out
New entrants face a low threat in Collegium Pharmaceutical, Inc.'s pain market because FDA, DEA, and state controlled-substance rules raise time, cost, and risk. Opioid litigation has topped $50 billion, and generics fill about 90% of U.S. prescriptions, so a new brand must spend heavily before it can win trust, formulary access, and share.
| Barrier | Data |
|---|---|
| Opioid settlements | $50B+ |
| U.S. prescriptions on generics | ~90% |
| Core entry hurdles | FDA, DEA, state rules |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.